Acorn PharmaTech

Acorn PharmaTech is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule therapeutics for oncology and autoimmune diseases. The company utilizes a structure-based drug design approach to develop highly selective inhibitors for validated biological targets, including BTK, FLT3, and JAK1. With a dual-operational model spanning the United States and China, Acorn PharmaTech aims to address significant unmet medical needs in hematologic malignancies and inflammatory conditions. Its lead clinical programs, such as AC-003 and AC-0527, are currently undergoing evaluation in human trials to establish safety and efficacy. The company is positioned as a cross-border developer leveraging global R&D resources to accelerate its pipeline toward commercialization.